↩ Skip to Main Content ↩ Skip to Navigation
Home
About Us ▼ |
  • Director Profile
  • Introduction
  • Former Directors
  • Administration
  • IT Support
  • Research Monitoring & Evaluation Cell
  • Field Stations ▼
    • ICMR-NIV Bangalore Unit
    • ICMR-NIV Mumbai Unit
    • ICMR–NIV Kerala Unit
  • Zonal NIV's
  • Committees
  • Milestones
Functional Groups ▼ |
  • Basic Virology
  • Antiviral Research
  • Development of New Diagnostic Assays
  • Virus Repository
  • Preclinical evaluation of counter measures & Vaccine Research on novel pathogens
  • Surveillance, Outbreak Investigation, and Pandemic Preparedness
Facilities ▼ |
  • Animal Facility
  • Diagnostic Reagent Facility
  • BSL-3 Facility
  • BSL-4 Facility
  • MBSL-3 Facility
  • Electron Microscopy Facility
  • Next Generation Sequencing (NGS)
  • Nakshatra High Performance Computing
Products & Patents ▼ |
  • Patents
  • Major Technologies Commercialized
  • Technologies-Developed
Academics ▼ |
  • Academic Cell
  • M.Sc. Virology Program
  • PhD and Post Doctoral Fellowship Programs
Publications ▼ |
  • Publications
  • Annual Reports
  • Monographs/Books/Booklets
  • Guidelines
Resource Centres ▼ |
  • National Influenza Centre
  • Virus Repository and Resource Centre
  • Virus Research And Diagnostic Laboratories (RC-VRDL)
Current Activities ▼ |
  • Services /Outbreak Investigations
  • Workshop/Conferences
Collaborations ▼ |
  • National
  • International
Notifications ▼ |
  • Vacancies
  • Tenders
  • Employee Corner
  • Forms
  • Circulars
  • RTI
Media ▼ |
  • Announcements
  • News updates
  • Photo Gallery
  • Videos
Awards |
Contact Us

Site Search

  • Home   >
  • Functional Groups

Development of New Diagnostic Assays

Development of Novel Diagnostic Assays (DNDA) Group: The Development of Novel Diagnostic Assays (DNDA) Group is committed to advancing the frontiers of viral diagnostics by developing innovative, rapid, accurate, affordable, and field-deployable diagnostic technologies for emerging, re-emerging, and endemic viral diseases of public health importance. The group brings together multidisciplinary expertise in molecular virology, biotechnology, immunodiagnostics, genomics, bioengineering, and translational research to design, develop, optimize, validate, and translate next-generation diagnostic platforms that support disease surveillance, outbreak response, and patient care.

The group's research encompasses the entire diagnostic development pipeline—from biomarker discovery and assay design to analytical validation, clinical evaluation, technology transfer, and product translation. Major areas of research include Microfluidic Point-of-Care Testing (PoCT) platforms, RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification) assays, CRISPR-based diagnostics (CRISPR-Dx), SELEX-based protein quantification assays, multiplex real-time RT-PCR assays, serological and immunological assays, lateral flow immunoassay (LFA)-based rapid diagnostic kits, and other next-generation molecular diagnostic technologies. The group also focuses on identifying prognostic biomarkers, host-response signatures, and novel molecular targets that enable early diagnosis, disease severity prediction, and improved clinical management. The DNDA Group develops diagnostic solutions for a wide spectrum of medically important viral pathogens, including SARS-CoV-2, Ebola virus, Nipah virus, Mpox virus, Zika virus, Poliovirus, Dengue virus, Chikungunya virus, Influenza viruses, Crimean–Congo hemorrhagic fever virus (CCHFV), West Nile virus, Human Papillomavirus (HPV), Hepatitis viruses, Measles virus, Rubella virus, Kyasanur Forest Disease virus (KFDV), Chandipura virus, and other arboviruses of national and global public health significance.

Vision: To be a Centre of Excellence in the development of innovative molecular, immunological, and point-of-care diagnostic technologies that enable rapid detection, surveillance, and control of emerging, re-emerging, and endemic viral diseases, thereby strengthening public health preparedness, advancing translational research, and improving patient care through accessible, reliable, high-quality, and affordable diagnostic solutions.
Read More Read Less

Key Activities

  • Antibody-Based Assays: Developing serological tests to detect host immune responses against pathogens.
  • Antigen-Based Assays: Designing diagnostic methods that directly detect pathogen-specific proteins for rapid diagnosis.
  • Nucleic Acid-Based Assays: Creating molecular diagnostic techniques to identify and quantify pathogen genetic material with high sensitivity and specificity.
  • Cell-Based Assays: Establishing cellular systems to evaluate pathogen detection, infection dynamics, and diagnostic performance.

Scientists

Dr. Shyam Sundar Nandi

Dr. Shyam Sundar Nandi

Scientist-E


Expertise

Molecular Virology, New Vaccine Development

☎ 02026006290
✉ nandi.shyamsundar@icmr.gov.in
Dr. Alagarasu Kalichamy

Dr. Alagarasu Kalichamy

Scientist-E


Expertise

Microbiology, Immunology and Immunogenetics

☎ 020-26006256
✉ alagarasu.k@gov.in
Dr. Anita Shete-Aich

Dr. Anita Shete-Aich

Scientist-E


Expertise

Microbiology, Next generation sequencing, assay developments

☎ 020-25906830
✉ sheteaich.a-niv@gov.in
Dr. Tejaswini Mahesh Deshmukh

Dr. Tejaswini Mahesh Deshmukh

Scientist-D


Expertise

Viral Hepatitis, Antiviral Vaccines, Viral Diagnostics & Host–Virus Interactions

☎ 020-26006823
✉ deshmukh.t@gov.in

• Head Office

ICMR National Institute of Virology
20/ A Dr. Ambedkar Road, Pune, Maharashtra - 411001

020-26006290 / 25906890

director[dot]niv[at]icmr[dot]gov[dot]in

• Pashan Office

ICMR National Institute of Virology
MCC 130/1, Sus Road, Pashan, Pune, Maharashtra - 411021

020-25906890

director[dot]niv[at]icmr[dot]gov[dot]in

Visitor Count - 6612189

Website Policy

Contact Us

Terms & Conditions

© 2026   ICMR-NIV.  All Rights Reserved.

Accessibility options

Feedback Form